Literature DB >> 33656540

Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.

Juan José Lahuerta1, Bruno Paiva2, Ana Jiménez-Ubieto3, José Sánchez-Pina3, María-Victoria Mateos4, Joan Bladé5, Jesús F San-Miguel2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33656540      PMCID： PMC7948301          DOI： 10.1182/bloodadvances.2020003996

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  28 in total

Review 1.  Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Authors:  J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 2.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

3.  Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.

Authors:  C Fernández de Larrea; R Jiménez; L Rosiñol; E Giné; N Tovar; M T Cibeira; F Fernández-Avilés; C Martínez; M Rovira; J Bladé
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

4.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

5.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Authors:  Michel Attal; Paul G Richardson; S Vincent Rajkumar; Jesus San-Miguel; Meral Beksac; Ivan Spicka; Xavier Leleu; Fredrik Schjesvold; Philippe Moreau; Meletios A Dimopoulos; Jeffrey Shang-Yi Huang; Jiri Minarik; Michele Cavo; H Miles Prince; Sandrine Macé; Kathryn P Corzo; Frank Campana; Solenn Le-Guennec; Franck Dubin; Kenneth C Anderson
Journal:  Lancet       Date:  2019-11-14       Impact factor: 79.321

6.  Prognostic factors in multiple myeloma.

Authors:  R Alexanian; S Balcerzak; J D Bonnet; E A Gehan; A Haut; J S Hewlett; R W Monto
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

7.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

8.  Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Authors:  Meletios A Dimopoulos; Antonio Palumbo; Paolo Corradini; Michele Cavo; Michel Delforge; Francesco Di Raimondo; Katja C Weisel; Albert Oriol; Markus Hansson; Angelo Vacca; María Jesús Blanchard; Hartmut Goldschmidt; Chantal Doyen; Martin Kaiser; Mario Petrini; Pekka Anttila; Anna Maria Cafro; Reinier Raymakers; Jesus San-Miguel; Felipe de Arriba; Stefan Knop; Christoph Röllig; Enrique M Ocio; Gareth Morgan; Neil Miller; Mathew Simcock; Teresa Peluso; Jennifer Herring; Lars Sternas; Mohamed H Zaki; Philippe Moreau
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

9.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

10.  Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Authors:  J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998
View more
  1 in total

1.  Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.

Authors:  Rafael Alonso; Juan José Lahuerta
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.